# Grit Biotechnology clinical trials: 30 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with Grit Biotechnology as lead sponsor, 17 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Grit Biotechnology: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/grit-biotechnology

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 17
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 30, 2026 | NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With... | Grit Biotechnology | Early phase 1 | Not yet recruiting | Relapsed/Refractory Acute Myeloid Leukemia (AML) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676006) |
| April 16, 2026 | NCT07534813 | A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent... | Grit Biotechnology | Not applicable | Withdrawn | Advanced Solid Tumors | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07534813) |
| February 5, 2026 | NCT07389499 | A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases | Grit Biotechnology | Early phase 1 | Not yet recruiting | IgA Nephropathy (IgAN), Membranous Nephropathy, ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389499) |
| January 12, 2026 | NCT07333118 | A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune... | Grit Biotechnology | Early phase 1 | Recruiting | Moderate to Severe Refractory Autoimmune Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333118) |
| November 28, 2025 | NCT07253259 | A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic... | Grit Biotechnology | Early phase 1 | Recruiting | cGVHD | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07253259) |
| October 3, 2025 | NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell... | Grit Biotechnology | Early phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL)... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205315) |
| August 20, 2025 | NCT07132112 | GT719 Injection for Moderate to Severe Refractory Autoimmune Disease | Grit Biotechnology | Early phase 1 | Recruiting | Auto Immune Disease | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07132112) |
| August 20, 2025 | NCT07131254 | A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory... | Grit Biotechnology | Early phase 1 | Recruiting | Hematological Malignancy (Leukemia- Lymphoma) | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07131254) |
| August 14, 2025 | NCT07122076 | GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases | Grit Biotechnology | Early phase 1 | Recruiting | Autoimmune Diseases | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07122076) |
| June 13, 2025 | NCT07021209 | GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases | Grit Biotechnology | Phase 1 | Recruiting | Neurological Autoimmune Diseases | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07021209) |
| April 29, 2025 | NCT06948981 | GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies | Grit Biotechnology | Phase 1/2 | Recruiting | Hematological Malignancy (Leukemia- Lymphoma) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948981) |
| February 19, 2025 | NCT06834542 | Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors | Grit Biotechnology | Early phase 1 | Terminated | Adult Gynecological Tumors | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06834542) |
| February 11, 2025 | NCT06819293 | IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma | Grit Biotechnology | Phase 1 | Recruiting | Advanced Clear Renal Cell Carcinoma, Adult | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819293) |
| February 11, 2025 | NCT06819280 | Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer | Grit Biotechnology | Not applicable | Recruiting | Adult | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819280) |
| July 25, 2024 | NCT06519669 | Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer | Grit Biotechnology | Not applicable | Terminated | Adult, Lung Cancer | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06519669) |
| July 9, 2024 | NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma | Grit Biotechnology | Phase 1 | Terminated | Advanced Lung Adenocarcinoma；Adult | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06491225) |
| June 11, 2024 | NCT06453057 | Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours | Grit Biotechnology | Not applicable | Recruiting | Adult | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06453057) |
| May 3, 2024 | NCT06397963 | Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours | Grit Biotechnology | Not applicable | Recruiting | Solid Tumor, Adult | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06397963) |
| February 5, 2024 | NCT06241781 | Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer | Grit Biotechnology | Phase 2 | Recruiting | Recurrent or Metastatic Cervical Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06241781) |
| January 31, 2024 | NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer | Grit Biotechnology | Not applicable | Terminated | Adult, Non-small Cell Lung Cancer | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06235242) |
| January 5, 2024 | NCT06191900 | Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer) | Grit Biotechnology | Not applicable | Terminated | Adult, Gynecological Tumors | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191900) |
| January 5, 2024 | NCT06190275 | Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors | Grit Biotechnology | Not applicable | Recruiting | HNSCC | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06190275) |
| November 24, 2023 | NCT06145802 | Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological... | Grit Biotechnology | Not applicable | Withdrawn | Solid Tumor, Gynecological Tumors | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06145802) |
| November 22, 2023 | NCT06144671 | Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors | Grit Biotechnology | Phase 1/2 | Recruiting | Advanced Solid Tumors | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06144671) |
| October 23, 2023 | NCT06094426 | Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors | Grit Biotechnology | Early phase 1 | Terminated | Solid Tumor, Adult, GT316 | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094426) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 11 |
| Phase 1 | 6 |
| Phase 1/2 | 3 |
| Phase 2 | 1 |
| Not applicable | 9 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 15 |
| Terminated | 9 |
| Withdrawn | 2 |
| Active not recruiting | 2 |
| Not yet recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hematologic Neoplasms | 2 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Autoimmune Diseases | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lung Neoplasms | 1 |
| Recurrence | 1 |
| Uterine Cervical Neoplasms | 1 |
| Glomerulonephritis, IGA | 1 |
| Glomerulonephritis, Membranous | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Burkitt Lymphoma | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Lymphoma, B-Cell | 1 |
| Anemia, Hemolytic, Autoimmune | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Oral and maxillofacial surgery practices in the United States](https://specstream.ai/data/businesses/oral-and-maxillofacial-surgery-practices/united-states)
- [Spring suppliers in the United States](https://specstream.ai/data/businesses/spring-suppliers/united-states)
- [Ayurveda clinics in the United States](https://specstream.ai/data/businesses/ayurveda-clinics/united-states)
- [Debt relief companies in the United States](https://specstream.ai/data/businesses/debt-relief-companies/united-states)
- [Hospital equipment suppliers in the United States](https://specstream.ai/data/businesses/hospital-equipment-suppliers/united-states)
